40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy. (October 2019)

• Record Type: Journal Article
• Authors: Biziotis, Olga-Demetra; Tsakiridis, Evangelia - Evelyn; Broadfield, Lindsay; Farrell, Thomas; Menjolian, Gabe; Mathurin, Tammy; Mekhaeil, Bassem; Zacharidis, Panagiotis; Muti, Paola; Abdulkarim, Bassam; Steinberg, Gregory; Tsakiridis, Theodoros
• Is Part Of: Radiotherapy and oncology. Volume 139(2019)Supplement 1
• Page Start: S20
• Publication Date: 2019-10
• Subjects: Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/S0167-8140(19)33327-4
• Languages: English
• ISSNs: 0167-8140